Strong Investment Backing Cellestia Biotech has successfully attracted significant funding, including a CHF 20 million Series B round led by prominent investors like PPF Group and Partners Investment, demonstrating strong investor confidence and potential for expansion into new studies and markets.

Innovative Clinical Pipeline The company's promising clinical-stage drug candidate CB-103, targeting both autoimmune diseases and multi-drug resistant cancers, presents multiple opportunities for collaboration with healthcare providers and pharmaceutical partners involved in oncology and immunology.

Recent Strategic Expansion Integration with TVM Capital GmbH signals a strategic move to enhance financial resources and accelerate product development, creating avenues for joint ventures, licensing, or co-marketing with other biotech and pharma firms aiming to expand their therapeutic portfolios.

Research & Publications Cellestia's recent publication on CB-103's efficacy in breast cancer preclinical models positions it as a scientifically credible partner for institutions seeking innovative solutions in cancer therapy and transcriptional targeting.

Recognition & Awards Receiving the Horizon 2020 Seal of Excellence highlights the company's innovative project potential, making it an attractive partner for European programs, grants, and collaborations focusing on groundbreaking biotech research.